# US 2023/0058054 A1 · Crispr/cas system and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058054 A1
- Document ID: US20230058054A1
- Status: Published application
- Kind: A1
- Application number: 17/851,030
- Filed: 2022-06-28
- Published: 2023-02-23
- Earliest claimed: 2021-06-29
- Assignees: HuiGene Therapeutics Co., Ltd.
- Applicants: HuiGene Therapeutics Co., Ltd.
- Inventors: Xing Wang
- Web page: https://patentgrep.com/patent/US20230058054A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/907: {in mammalian cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/85: containing an RNA binding domain
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13c, Cas13d, Cas13e, or Cas 13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRNA) or crRNA. The novel Cas effector proteins are among the smallest of the known Cas effector proteins, at about 800-900 amino acids in size, and are thus uniquely suitable for delivery using vectors of small capacity, such as an AAV vector.

## Claims

### Claim 1

A Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas complex, comprising:
(1) an RNA guide sequence comprising a spacer sequence capable of hybridizing to a target RNA, and a direct repeat (DR) sequence 5′ or 3′ to the spacer sequence; and,
(2) a CRISPR-associated protein (Cas) having an amino acid sequence of any one of SEQ ID NOs: 2-7 and 9-17, or a derivative or functional fragment of said Cas;
wherein the Cas, the derivative, and the functional fragment of said Cas, are capable of (i) binding to the RNA guide sequence and (ii) targeting the target RNA, with the proviso that the spacer sequence is not 100% complementary to a naturally-occurring bacterialphage nucleic acid when the complex comprises the Cas of any one of SEQ ID NOs: 2-7 and 9-17.

### Claim 2 (depends on 1)

The CRISPR-Cas complex of claim 1, wherein the DR sequence has substantially the same secondary structure as the secondary structure of any one of SEQ ID NOs: 19-24 and 26-34.

### Claim 3 (depends on 1)

The CRISPR-Cas complex of claim 1, wherein the DR sequence is encoded by any one of SEQ ID NOs: 19-24 and 26-34.

### Claim 4 (depends on 1, 2)

The CRISPR-Cas complex of claim 1, 2, or 3, wherein the target RNA is encoded by a eukaryotic DNA.

### Claim 5 (depends on 4)

The CRISPR-Cas complex of claim 4, wherein the eukaryotic DNA is a non-human mammalian DNA, a non-human primate DNA, a human DNA, a plant DNA, an insect DNA, a bird DNA, a reptile DNA, a rodent DNA, a fish DNA, a worm/nematode DNA, a yeast DNA.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The CRISPR-Cas complex of any one of claims 1-5, wherein the target RNA is an mRNA.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The CRISPR-Cas complex of any one of claims 1-6, wherein the spacer sequence is between 15-55 nucleotides, between 25-35 nucleotides, or about 30 nucleotides.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The CRISPR-Cas complex of any one of claims 1-7, wherein the spacer sequence is 90-100% complementary to the target RNA.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The CRISPR-Cas complex of any one of claims 1-8, wherein the derivative is at least about 90%, 95%, 96%, 97%, 98%, 99% identical to any one of SEQ ID NOs: 2-7 and 9-17, or comprises conserved amino acid substitutions of one or more residues of any one of SEQ ID NOs: 2-7 and 9-17.

### Claim 10 (depends on 9)

The CRISPR-Cas complex of claim 9, wherein the derivative comprises only conserved amino acid substitutions.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The CRISPR-Cas complex of any one of claims 1-10, wherein the derivative has identical sequence to wild-type Cas of any one of SEQ ID NOs: 2-7 and 9-17 in the HEPN domain or the RXXXXH motif.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The CRISPR-Cas complex of any one of claims 1-9, wherein the derivative is capable of binding to the RNA guide sequence hybridized to the target RNA, but has no RNase catalytic activity due to a mutation in the RNase catalytic site of the Cas.

### Claim 13 (depends on 12)

The CRISPR-Cas complex of claim 12, wherein the derivative has an N-terminal deletion of no more than 210 residues, and/or a C-terminal deletion of no more than 180 residues.

### Claim 14 (depends on 13)

The CRISPR-Cas complex of claim 13, wherein the derivative has an N-terminal deletion of about 180 residues, and/or a C-terminal deletion of about 150 residues.

### Claim 15 (depends on 12, 13, 14)

The CRISPR-Cas complex of any one of claims 12-14, wherein the derivative further comprises an RNA base-editing domain.

### Claim 16 (depends on 15)

The CRISPR-Cas complex of claim 15, wherein the RNA base-editing domain is an adenosine deaminase, such as a double-stranded RNA-specific adenosine deaminase (e.g., ADAR1 or ADAR2); apolipoprotein B mRNA editing enzyme; catalytic polypeptide-like (APOBEC); or activation-induced cytidine deaminase (AID).

### Claim 17 (depends on 16)

The CRISPR-Cas complex of claim 16, wherein the ADAR has E488Q/T375G double mutation or is ADAR2DD.

### Claim 18 (depends on 15, 16, 17)

The CRISPR-Cas complex of any one of claims 15-17, wherein the base-editing domain is further fused to an RNA-binding domain, such as MS2.

### Claim 19 (depends on 12, 13, 14)

The CRISPR-Cas complex of any one of claims 12-14, wherein the derivative further comprises an RNA methyltransferase, a RNA demethylase, an RNA splicing modifier, a localization factor, or a translation modification factor.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The CRISPR-Cas complex of any one of claims 1-19, wherein the Cas, the derivative, or the functional fragment comprises a nuclear localization signal (NLS) sequence or a nuclear export signal (NES).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The CRISPR-Cas complex of any one of claims 1-20, wherein targeting of the target RNA results in a modification of the target RNA.

### Claim 22 (depends on 21)

The CRISPR-Cas complex of claim 21, wherein the modification of the target RNA is a cleavage of the target RNA.

### Claim 23 (depends on 21)

The CRISPR-Cas complex of claim 21, wherein the modification of the target RNA is deamination of an adenosine (A) to an inosine (I).

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The CRISPR-Cas complex of any one of claims 1-23, further comprising a target RNA comprising a sequence capable of hybridizing to the spacer sequence.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A fusion protein, comprising (1) the Cas, the derivative thereof, or the functional fragment thereof, of any one of claims 1-24, and (2) a heterologous functional domain.

### Claim 26 (depends on 25)

The fusion protein of claim 25, wherein the heterologous functional domain comprises: a nuclear localization signal (NLS), a reporter protein or a detection label (e.g., GST, HRP, CAT, GFP, HcRed, DsRed, CFP, YFP, BFP), a localization signal, a protein targeting moiety, a DNA binding domain (e.g., MBP, Lex A DBD, Gal4 DBD), an epitope tag (e.g., His, myc, V5, FLAG, HA, VSV-G, Trx, etc), a transcription activation domain (e.g., VP64 or VPR), a transcription inhibition domain (e.g., KRAB moiety or SID moiety), a nuclease (e.g., FokI), a deamination domain (e.g., ADAR1, ADAR2, APOBEC, AID, or TAD), a methylase, a demethylase, a transcription release factor, an HDAC, a polypeptide having ssRNA cleavage activity, a polypeptide having dsRNA cleavage activity, a polypeptide having ssDNA cleavage activity, a polypeptide having dsDNA cleavage activity, a DNA or RNA ligase, or any combination thereof.

### Claim 27 (depends on 25, 26)

The fusion protein of claim 25 or 26, wherein the heterologous functional domain is fused N-terminally, C-terminally, or internally in the fusion protein.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A conjugate, comprising (1) the Cas, the derivative thereof, or the functional fragment thereof, of any one of claims 1-24, conjugated to (2) a heterologous functional moiety.

### Claim 29 (depends on 28)

The conjugate of claim 28, wherein the heterologous functional moiety comprises: a nuclear localization signal (NLS), a reporter protein or a detection label (e.g., GST, HRP, CAT, GFP, HcRed, DsRed, CFP, YFP, BFP), a localization signal, a protein targeting moiety, a DNA binding domain (e.g., MBP, Lex A DBD, Gal4 DBD), an epitope tag (e.g., His, myc, V5, FLAG, HA, VSV-G, Trx, etc), a transcription activation domain (e.g., VP64 or VPR), a transcription inhibition domain (e.g., KRAB moiety or SID moiety), a nuclease (e.g., FokI), a deamination domain (e.g., ADAR1, ADAR2, APOBEC, AID, or TAD), a methylase, a demethylase, a transcription release factor, an HDAC, a polypeptide having ssRNA cleavage activity, a polypeptide having dsRNA cleavage activity, a polypeptide having ssDNA cleavage activity, a polypeptide having dsDNA cleavage activity, a DNA or RNA ligase, or any combination thereof.

### Claim 30 (depends on 28, 29)

The conjugate of claim 28 or 29, wherein the heterologous functional moiety is conjugated N-terminally, C-terminally, or internally with respect to the Cas, the derivative thereof, or the functional fragment thereof.

### Claim 31

A polynucleotide encoding any one of SEQ ID NOs: 2-7 and 9-17, or a derivative thereof, or a functional fragment thereof, or a fusion protein thereof, or a polynucleotide at least about 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical thereto, provided that the polynucleotide is not any one of SEQ ID NOs: 1 and 8.

### Claim 32 (depends on 31)

The polynucleotide of claim 31, which is codon-optimized for expression in a cell.

### Claim 33 (depends on 32)

The polynucleotide of claim 32, wherein the cell is a eukaryotic cell.

### Claim 34

A non-naturally occurring polynucleotide comprising a derivative of any one of SEQ ID NOs: 19-24 and 26-34, wherein said derivative (i) has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) nucleotides additions, deletions, or substitutions compared to any one of SEQ ID NOs: 19-24 and 26-34; (ii) has at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 97% sequence identity to any one of SEQ ID NOs: 19-24 and 26-34; (iii) hybridize under stringent conditions with any one of SEQ ID NOs: 19-24 and 26-34 or any of (i) and (ii); or (iv) is a complement of any of (i)-(iii), provided that the derivative is not any one of SEQ ID NOs: 19-24 and 26-34, and that the derivative encodes an RNA (or is an RNA) that has maintained substantially the same secondary structure as any of the RNA encoded by SEQ ID NOs: 19-24 and 26-34.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 34)

The non-naturally occurring polynucleotide of claim 34, wherein the derivative functions as a DR sequence for any one of the Cas, the derivative thereof, or the functional fragment thereof, of any one of claims 1-24.

### Claim 36 (depends on 31, 32, 33, 34, 35)

A vector comprising the polynucleotide of any one of claims 31-35.

### Claim 37 (depends on 36)

The vector of claim 36, wherein the polynucleotide is operably linked to a promoter and optionally an enhancer.

### Claim 38 (depends on 37)

The vector of claim 37, wherein the promoter is a constitutive promoter, an inducible promoter, a ubiquitous promoter, or a tissue specific promoter.

### Claim 39 (depends on 36, 37, 38)

The vector of any one of claims 36-38, which is a plasmid.

### Claim 40 (depends on 36, 37, 38)

The vector of any one of claims 36-38, which is a retroviral vector, a phage vector, an adenoviral vector, a herpes simplex viral (HSV) vector, an AAV vector, or a lentiviral vector.

### Claim 41 (depends on 40)

The vector of claim 40, wherein the AAV vector is a recombinant AAV vector of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 36, 37, 38, 39, 40, 41)

A delivery system comprising (1) a delivery vehicle, and (2) the CRISPR-Cas complex of any one of claims 1-24, the fusion protein of any one of claims 25-27, the conjugate of any one of claims 28-30, the polynucleotide of any one of claims 31-33, or the vector of any one of claims 36-41.

### Claim 43 (depends on 42)

The delivery system of claim 42, wherein the delivery vehicle is a nanoparticle, a liposome, an exosome, a microvesicle, or a gene-gun.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 36, 37, 38, 39, 40, 41)

A cell or a progeny thereof, comprising the CRISPR-Cas complex of any one of claims 1-24, the fusion protein of any one of claims 25-27, the conjugate of any one of claims 28-30, the polynucleotide of any one of claims 31-33, or the vector of any one of claims 36-41.

### Claim 45 (depends on 44)

The cell or progeny thereof of claim 44, which is a eukaryotic cell (e.g., a non-human mammalian cell, a human cell, or a plant cell) or a prokaryotic cell (e.g., a bacteria cell).

### Claim 46 (depends on 44, 45)

A non-human multicellular eukaryote comprising the cell of claim 44 or 45.

### Claim 47 (depends on 46)

The non-human multicellular eukaryote of claim 46, which is an animal (e.g., rodent or primate) model for a human genetic disorder.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of modifying a target RNA, the method comprising contacting the target RNA with the CRISPR-Cas complex of any one of claims 1-24, wherein the spacer sequence is complementary to at least 15 nucleotides of the target RNA; wherein the Cas, the derivative, or the functional fragment associates with the RNA guide sequence to form the complex; wherein the complex binds to the target RNA; and wherein upon binding of the complex to the target RNA, the Cas, the derivative, or the functional fragment modifies the target RNA.

### Claim 49 (depends on 48)

The method of claim 48, wherein the target RNA is modified by cleavage by the Cas.

### Claim 50 (depends on 48)

The method of claim 48, wherein the target RNA is modified by deamination by a derivative comprising a double-stranded RNA-specific adenosine deaminase.

### Claim 51 (depends on 48, 49, 50)

The method of any one of claim 48-50, wherein the target RNA is an mRNA, a tRNA, an rRNA, a non-coding RNA, an lncRNA, or a nuclear RNA.

### Claim 52 (depends on 48, 49, 50, 51)

The method of any one of claims 48-51, wherein upon binding of the complex to the target RNA, the Cas, the derivative, and the functional fragment does not exhibit substantial (or detectable) collateral RNase activity.

### Claim 53 (depends on 48, 49, 50, 51, 52)

The method of any one of claims 48-52, wherein the target RNA is within a cell.

### Claim 54 (depends on 53)

The method of claim 53, wherein the cell is a cancer cell.

### Claim 55 (depends on 53)

The method of claim 53, wherein the cell is infected with an infectious agent.

### Claim 56 (depends on 55)

The method of claim 55, wherein the infectious agent is a virus, a prion, a protozoan, a fungus, or a parasite.

### Claim 57 (depends on 53, 54, 55, 56)

The method of any one of claims 53-56, wherein the CRISPR-Cas complex is encoded by a first polynucleotide encoding any one of SEQ ID NOs: 2-7 and 9-17, or a derivative or functional fragment thereof, and a second polynucleotide comprising any one of SEQ ID NOs: 19-24 and 26-34 and a sequence encoding a spacer RNA capable of binding to the target RNA, wherein the first and the second polynucleotides are introduced into the cell.

### Claim 58 (depends on 57)

The method of claim 57, wherein the first and the second polynucleotides are introduced into the cell by the same vector.

### Claim 59 (depends on 53, 54, 55, 56, 57, 58)

The method of any one of claims 53-58, which cases one or more of: (i) in vitro or in vivo induction of cellular senescence; (ii) in vitro or in vivo cell cycle arrest; (iii) in vitro or in vivo cell growth inhibition and/or cell growth inhibition; (iv) in vitro or in vitro induction of anergy; (v) in vitro or in vitro induction of apoptosis; and (vi) in vitro or in vitro induction of necrosis.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of treating a condition or disease in a subject in need thereof, the method comprising administering to the subject a composition comprising the CRISPR-Cas complex of any one of claims 1-24 or a polynucleotide encoding the same; wherein the spacer sequence is complementary to at least 15 nucleotides of a target RNA associated with the condition or disease; wherein the Cas, the derivative, or the functional fragment associates with the RNA guide sequence to form the complex; wherein the complex binds to the target RNA; and wherein upon binding of the complex to the target RNA, the Cas, the derivative or the functional fragment cleaves the target RNA, thereby treating the condition or disease in the subject.

### Claim 61 (depends on 60)

The method of claim 60, wherein the condition or disease is a cancer or an infectious disease.

### Claim 62 (depends on 61)

The method of claim 61, wherein the cancer is Wilms' tumor, Ewing sarcoma, a neuroendocrine tumor, a glioblastoma, a neuroblastoma, a melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, renal cancer, pancreatic cancer, lung cancer, biliary cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid carcinoma, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or urinary bladder cancer.

### Claim 63 (depends on 60, 61, 62)

The method of any one of claims 60-62, which is an in vitro method, an in vivo method, or an ex vivo method.

### Claim 64 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A cell or a progeny thereof, obtained by the method of any one of claims 48-59, wherein the cell and the progeny comprises a non-naturally existing modification (e.g., a non-naturally existing modification in a transcribed RNA of the cell/progeny).

### Claim 65 (depends on 25, 26, 27, 28, 29, 30)

A method to detect the presence of a target RNA, the method comprising contacting the target RNA with a composition comprising a fusion protein of any one of claims 25-27, or a conjugate of any one of claims 28-30, or a polynucleotide encoding the fusion protein, wherein the fusion protein or the conjugate comprises a detectable label (e.g., one that can be detected by fluorescence, Northern blot, or FISH) and a complexed spacer sequence capable of binding to the target RNA.

### Claim 66

A eukaryotic cell comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas complex, said CRISPR-Cas complex comprising:
(1) an RNA guide sequence comprising a spacer sequence capable of hybridizing to a target RNA, and a direct repeat (DR) sequence 3′ to the spacer sequence; and,
(2) a CRISPR-associated protein (Cas) having an amino acid sequence of any one of SEQ ID NOs: 2-7 and 9-17, or a derivative or functional fragment of said Cas;
wherein the Cas, the derivative, and the functional fragment of said Cas, are capable of (i) binding to the RNA guide sequence and (ii) targeting the target RNA.
